GeneMind Biosciences Company Limited announced that it has raised CNY 400,000,000 in a round of funding co-led by new investors, Guangzhou Kingmed Diagnostics Group Co., Ltd. and Shanghai Guoxin Investment Development Co. Ltd. on August 2, 2023. The transaction also included participation from new investors, Shenzhen High-Tech Investment Group Co., Ltd., Changzhou Shuangye Venture Capital, Hunan Caixin Capital Management Co., Ltd. and Guochuang Zhiyuan Private Equity Fund.
Guangzhou Kingmed Diagnostics Group Co., Ltd.
Equities
603882
CNE100002VW1
Healthcare Facilities & Services
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
38.35 CNY | -4.84% | -14.49% | -38.71% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.71% | 2.46B | |
-19.14% | 8.22B | |
+48.66% | 3.73B | |
-8.06% | 2.46B | |
-8.84% | 2.36B | |
-9.02% | 1.78B | |
-19.29% | 1.52B | |
-40.78% | 1.21B | |
+8.32% | 1.12B | |
-12.27% | 1.09B |
- Stock Market
- Equities
- 603882 Stock
- News Guangzhou Kingmed Diagnostics Group Co., Ltd.
- GeneMind Biosciences Company Limited announced that it has received CNY 400 million in funding from Guangzhou Kingmed Diagnostics Group Co., Ltd., Shanghai Guoxin Investment Development Co. Ltd., Shenzhen High-Tech Investment Group Co., Ltd., Changzhou Shuangye Venture Capital, Hunan Caixin Capital Management Co., Ltd. and other investor